Optimizing mRNA-Loaded Lipid Nanoparticles as a Potential Tool for Protein-Replacement Therapy

• Egile Nagusiak: Rocío Gambaro (Egilea), Ignacio Rivero Berti (Egilea), María José Limeres (Egilea), Cristián Huck-Iriart (Egilea), Malin Svensson (Egilea), Silvia Fraude (Egilea), Leah Pretsch (Egilea), Shutian Si (Egilea), Ingo Lieberwirth (Egilea), Stephan Gehring (Egilea), Maximiliano Cacicedo (Egilea), Germán Abel Islan (Egilea)
• Formatua: Liburua
• Argitaratua: MDPI AG, 2024-06-01T00:00:00Z.
• Gaiak: article
• Sarrera elektronikoa: Connect to this object online.

Lipid nanoparticles (LNPs) tailored for mRNA delivery were optimized to serve as a platform for treating metabolic diseases. Four distinct lipid mixes (LMs) were formulated by modifying various components: LM1 (ALC-0315/DSPC/Cholesterol/ALC-0159), LM2 (ALC-0315/DOPE/Cholesterol/ALC-0159), LM3 (ALC-0...